- 全部删除
- 您的购物车当前为空
RLX (PD 139530)是一种 PI3K/Akt/FoxO3a 信号抑制剂,对结肠癌等肿瘤细胞系具有抗癌活性,诱导亚g1阻滞和线粒体潜在损失,抑制肿瘤生长。RLX还具有止咳和抗哮喘的活性,能够减少BAL中嗜酸性粒细胞和总淋巴细胞,对A549细胞具有毒性。
RLX (PD 139530)是一种 PI3K/Akt/FoxO3a 信号抑制剂,对结肠癌等肿瘤细胞系具有抗癌活性,诱导亚g1阻滞和线粒体潜在损失,抑制肿瘤生长。RLX还具有止咳和抗哮喘的活性,能够减少BAL中嗜酸性粒细胞和总淋巴细胞,对A549细胞具有毒性。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 1,980 | In stock | |
5 mg | ¥ 4,920 | In stock | |
10 mg | ¥ 7,130 | In stock | |
25 mg | ¥ 10,600 | In stock | |
50 mg | ¥ 13,800 | In stock | |
100 mg | ¥ 17,500 | In stock |
RLX 相关产品
产品描述 | RLX (PD 139530) is a PI3K/Akt/FoxO3a signal inhibitor with anticancer activity against tumour cell lines such as colon cancer, inducing sub-G1 arrest and mitochondrial potential loss, thereby inhibiting tumour growth. RLX also exhibits antitussive and anti-asthmatic activity, reducing eosinophils and total lymphocytes in bronchoalveolar lavage (BAL) fluid, and exhibits toxicity toward A549 cells. |
别名 | THA-Q, THA Q, PD-139530, PD139530, PD 139530 |
分子量 | 214.26 |
分子式 | C13H14N2O |
CAS No. | 4425-23-4 |
Smiles | O=C1C=2C=CC=CC2N=C3N1CCCCC3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容